MiR-181b sensitizes glioma cells to teniposide by targeting MDM2

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Sun, Yan chang ^a,b,d   Wang, Jing ^a,c   Guo, Cheng cheng ^a   Sai, Ke ^a   Wang, Jian ^a   Chen, Fu rong ^a   Yang, Qun ying ^a   Chen, Yin sheng ^a   Wang, Jie ^a   To, Tony Shing shun ^c   Zhang, Zong ping ^b   Mu, Yong gao ^a   Chen, Zhong ping ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d Hainan Provincial Nongken Hospital   (China)

Author keywords

Glioma; miR 181b; Mouse double minute 2 homolog (MDM2); Teniposide

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 181B; PROTEIN MDM2; TENIPOSIDE; UNCLASSIFIED DRUG; MDM2 PROTEIN, HUMAN; MIRN181 MICRORNA, HUMAN; TUMOR MARKER;

3' UNTRANSLATED REGION; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIZATION; DRUG TARGETING; GENE OVEREXPRESSION; GENE SILENCING; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; STABLE EXPRESSION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICRORNAS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TENIPOSIDE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84910086415     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-611     Document Type: Article

References (30)

1. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012, 26(8):756-784.
2. Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 2012, 14(7):819-829.
3. American Cancer Society Cancer facts and figures 2013 2013, Atlanta, GA: American Cancer Society, American Cancer Society.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, . European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-466. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups.
5. Mirimanoff RO. High-grade gliomas: reality and hopes. Chin J Cancer 2014, 33(1):1-3.
6. Qiu ZK, Shen D, Chen YS, Yang QY, Guo CC, Feng BH, Chen ZP. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chin J Cancer 2013, 33(2):115-122.
7. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269.
8. Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, You Y. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 2008, 1236:185-193.
9. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005, 334(4):1351-1358.
10. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germano A, Vita G, Tomasello F. miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 2009, 93(3):325-332.
11. Li P, Lu X, Wang Y, Sun L, Qian C, Yan W, Liu N, You Y, Fu Z. MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. J Biomed Res 2010, 24(6):436-443.
12. Adiga SK, Jagetia GC. Effect of teniposide (VM-26) on the cell survival, micronuclei-induction and lactate dehydrogenase activity on V79 cells. Toxicology 1999, 138(1):29-41.
13. Stewart DJ, Richard MT, Hugenholtz H, Dennery J, Nundy D, Prior J, Montpetit V, Hopkins HS. Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol. J Neurooncol 1984, 2(4):315-324.
14. You Y. Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Des 2005, 11(13):1695-1717.
15. Li J, Chen W, Zhang P, Li N. Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma. World J Surg Oncol 2006, 4:41.
16. Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vince GH, Warmuth-Metz M, Kolbl O, Flentje M. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer 2006, 6:247.
17. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5(3):219-234.
18. Brassesco MS, Valera ET, Neder L, Castro-Gamero AM, Arruda D, Machado HR, Sakamoto-Hojo ET, Tone LG. Polyploidy in atypical grade II choroid plexus papilloma of the posterior fossa. Neuropathology 2009, 29(3):293-298.
19. Wang J, Sai K, Chen FR, Chen ZP. miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemother Pharmacol 2013, 72(1):147-158.
20. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009, 325(5944):1134-1138.
21. Guo JX, Tao QS, Lou PR, Chen XC, Chen J, Yuan GB. miR-181b as a potential molecular target for anticancer therapy of gastric neoplasms. Asian Pac J Cancer Prev 2012, 13(5):2263-2267.
22. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, Ghoshal K. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2009, 29(12):1787-1797.
23. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M. Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights 2006, 2:113-121.
24. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, Shao N, Qu H, Yang C, Zhang Y, Wang Q, Wang R, Zen K, Zhang CY, Zhang J, Yang Y. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 2010, 46(9):1640-1649.
25. Tao T, Wang Y, Luo H, Yao L, Wang L, Wang J, Yan W, Zhang J, Wang H, Shi Y, Yin Y, Jiang T, Kang C, Liu N, You Y. Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. Eur J Cancer 2013, 49(14):3055-3063.
26. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J. Non-coding MicroRNAs hsa-let-7 g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics 2006, 3(5):317-324.
27. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127(11):2520-2529.
28. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, Volinia S, Taccioli C, Kipps TJ, Croce CM. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 2011, 118(11):3072-3079.
29. Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, Liu P, Hong M, Miao KR, Xu W. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 2012, 33(7):1294-1301.
30. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387(6630):296-299.